Literature DB >> 25653413

Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial.

Sue C Kehl1, Michael J Dowzicky2.   

Abstract

The Tigecycline Evaluation and Surveillance Trial (TEST) was designed to monitor susceptibility to commonly used antimicrobial agents among important pathogens. We report here on susceptibility among Gram-negative pathogens collected globally from pediatric patients between 2004 and 2012. Antimicrobial susceptibility was determined using guidelines published by the Clinical and Laboratory Standards Institute (CLSI). Most Enterobacteriaceae showed high rates of susceptibility (>95%) to amikacin, tigecycline, and the carbapenems (imipenem and meropenem); 90.8% of Acinetobacter baumannii isolates were susceptible to minocycline, and susceptibility rates were highest in North America, Europe, and Asia/Pacific Rim. Amikacin was the most active agent against Pseudomonas aeruginosa (90.4% susceptibility), with susceptibility rates being highest in North America. Extended-spectrum β-lactamases (ESBLs) were reported for 11.0% of Escherichia coli isolates and 24.2% of Klebsiella pneumoniae isolates globally, with rates reaching as high as 25.7% in the Middle East and >43% in Africa and Latin America, respectively. Statistically significant (P<0.01) differences in susceptibility rates were noted between pediatric age groups (1 to 5 years, 6 to 12 years, or 13 to 17 years of age), globally and in some regions, for all pathogens except Haemophilus influenzae. Significant (P<0.01) differences were reported for all pathogens globally and in most regions, considerably more frequently, when pediatric and adult susceptibility results were compared. Amikacin, tigecycline, and the carbapenems were active in vitro against most Gram-negative pathogens collected from pediatric patients; A. baumannii and P. aeruginosa were susceptible to fewer antimicrobial agents. Susceptibility rates among isolates from pediatric patients were frequently different from those among isolates collected from adults.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25653413      PMCID: PMC4365249          DOI: 10.1128/JCM.03184-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Rapid spread of multiresistant Acinetobacter baumannii isolates in intensive care units (ICUs) and in vitro activity of colistin and tigecycline.

Authors:  Giovanni Buccoliero; Elisabetta Morelli; Gaetano Lonero; Chiara Romanelli; Francesco Resta; Salvatore Pisconti
Journal:  Infez Med       Date:  2012-12

2.  Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study.

Authors:  Jay Purdy; Sylvie Jouve; Jean Li Yan; Ivana Balter; Nathalie Dartois; C Angel Cooper; Joan Korth-Bradley
Journal:  Clin Ther       Date:  2012-01-16       Impact factor: 3.393

3.  Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008-2010.

Authors:  Sibylle H Lob; Robert E Badal; Samuel K Bouchillon; Stephen P Hawser; Meredith A Hackel; Daryl J Hoban
Journal:  Surg Infect (Larchmt)       Date:  2013-03-29       Impact factor: 2.150

4.  Community-acquired bloodstream infections among paediatric patients admitted to an Italian tertiary referral centre: a prospective survey.

Authors:  Carmelina Calitri; Silvia Virano; Carlo Scolfaro; Irene Raffaldi; Gianfranco De Intinis; Gabriella Gregori; Manuela Bianciotto; Pier-Angelo Tovo
Journal:  Infez Med       Date:  2012-09

5.  Multidrug-resistant Acinetobacter baumannii infection in children.

Authors:  Maia De Luca; Giulia Angelino; Francesca Ippolita Calò Carducci; Alessandra Martino; Stefania Bernardi; Paola Bernaschi; Michaela Carletti; Patrizia D'Argenio; Paolo Palma
Journal:  BMJ Case Rep       Date:  2011-08-11

6.  [Experience with tigecycline compassionate use in pediatric patients infected with carbapenem resistant Klebsiella pneumoniae].

Authors:  Isabel C Hurtado; Mónica Trujillo; Andrea Restrepo; Carlos Garcés; Carolina Tamayo; Juan G Mesa
Journal:  Rev Chilena Infectol       Date:  2012-06       Impact factor: 0.520

7.  Epidemiology and antibacterial susceptibility patterns of bloodstream infections, 2001-2004: an experience with BACTEC 9240 in Southern Iran.

Authors:  Aziz Japoni; Shohreh Farshad; Abdolvahab Alborzi; Mehdi Kalani; Nouradin Rafaatpour; Barat Oboodi; Bahman Pourabbas
Journal:  Pak J Biol Sci       Date:  2008-02-01

8.  Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies.

Authors:  Wolfgang R Heizmann; Hervé Dupont; Philippe Montravers; Xavier Guirao; Christian Eckmann; Matteo Bassetti; Miguel Sánchez García; Maria Rita Capparella; Damien Simoneau; Klaus Friedrich Bodmann
Journal:  J Antimicrob Chemother       Date:  2013-07       Impact factor: 5.790

9.  A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline.

Authors:  N C Gordon; D W Wareham
Journal:  J Antimicrob Chemother       Date:  2009-01-21       Impact factor: 5.790

10.  Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010.

Authors:  Stephen P Hawser; Robert E Badal; Samuel K Bouchillon; Daryl J Hoban; Douglas J Biedenbach; Rafael Cantón; David L Paterson
Journal:  Int J Antimicrob Agents       Date:  2013-01-08       Impact factor: 5.283

View more
  13 in total

1.  Tigecycline Nonsusceptibility Occurs Exclusively in Fluoroquinolone-Resistant Escherichia coli Clinical Isolates, Including the Major Multidrug-Resistant Lineages O25b:H4-ST131-H30R and O1-ST648.

Authors:  Toyotaka Sato; Yuuki Suzuki; Tsukasa Shiraishi; Hiroyuki Honda; Masaaki Shinagawa; Soh Yamamoto; Noriko Ogasawara; Hiroki Takahashi; Satoshi Takahashi; Yutaka Tamura; Shin-Ichi Yokota
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

2.  Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Jennifer H Han; Pranita D Tamma
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

3.  In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014.

Authors:  James A Karlowsky; Sibylle H Lob; Krystyna M Kazmierczak; Robert E Badal; Katherine Young; Mary R Motyl; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2017-03-15       Impact factor: 5.948

Review 4.  Future Challenges in Pediatric and Neonatal Sepsis: Emerging Pathogens and Antimicrobial Resistance.

Authors:  Laura Folgori; Julia Bielicki
Journal:  J Pediatr Intensive Care       Date:  2019-01-17

Review 5.  Intravenous Minocycline: A Review in Acinetobacter Infections.

Authors:  Sarah L Greig; Lesley J Scott
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

6.  Prevalence of Class D Carbapenemases among Extended-Spectrum β-Lactamases Producing Escherichia coli Isolates from Educational Hospitals in Shahrekord.

Authors:  Mohammad-Sadegh Damavandi; Abolfazl Gholipour; Mohammad Latif Pour
Journal:  J Clin Diagn Res       Date:  2016-05-01

7.  In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia.

Authors:  Aytekin Cikman; Baris Gulhan; Merve Aydin; Mehmet Resat Ceylan; Mehmet Parlak; Faruk Karakecili; Alper Karagoz
Journal:  Int J Med Sci       Date:  2015-08-14       Impact factor: 3.738

8.  Use of Carbapenems, Polymyxins, and Tigecycline in United States Children's Hospitals, 2010-2014.

Authors:  Kathleen Chiotos; Rachael K Ross; Jennifer H Han; Matthew Miller; Jeffrey S Gerber
Journal:  Open Forum Infect Dis       Date:  2017-03-09       Impact factor: 3.835

Review 9.  Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam.

Authors:  Matteo Bassetti; Maddalena Peghin; Alessio Mesini; Elio Castagnola
Journal:  Infect Drug Resist       Date:  2020-06-12       Impact factor: 4.003

10.  Antimicrobial susceptibility trends and evolution of isolates with extended spectrum β-lactamases among Gram-negative organisms recovered during the SMART study in Spain (2011-2015).

Authors:  R Cantón; E Loza; J Aznar; R Barrón-Adúriz; J Calvo; F J Castillo; E Cercenado; R Cisterna; F González-Romo; J L López-Hontangas; A I Suárez-Barrenechea; F Tubau; B Molloy; D López-Mendoza
Journal:  Rev Esp Quimioter       Date:  2018-03-12       Impact factor: 1.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.